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Abstract 17 
Background: Vasomotor symptoms (VMS) are the hallmarks of menopause, occurring in 18 
approximately 75% of postmenopausal women in the UK and are severe in 25%. 19 
Objectives: To identify which treatments are most clinically effective for the relief of VMS for non-20 
hysterectomized women in natural menopause. 21 
Search Strategy: English publications in MEDLINE, Embase and The Cochrane Library up to 13th 22 
January 2015 were searched.  23 
Selection Criteria: Randomized trials (RCTs) of treatments for women with a uterus for the 24 
outcomes of frequency of VMS (up to 26 weeks), vaginal bleeding and discontinuation.  25 
Data Collection and Analysis: Bayesian network meta-analysis (NMA) using mean ratios (MRs) and 26 
odd ratios (ORs).  27 
Main Results: Across the three networks, 47 RCTs of 16 treatment classes (N=8326 women) were 28 
included. When compared to placebo, transdermal oestradiol and progestogen (O+P) had the 29 
highest probability of being the most effective treatment for VMS relief (69.8%) (MR: 0.23 [95%CrI 30 
(0.09, 0.57)] whereas oral O+P was ranked lower than transdermal O+P, although oral and 31 
transdermal O+P were no different for this outcome (MR: 2.23 [95%CrI (0.7, 7.1)]. Isoflavones and 32 
black cohosh were more effective than placebo, though not significantly better than O+P. Not only 33 
were SSRIs or SNRIs found ineffective in relieving VMS but they also had significantly higher odds of 34 
discontinuation than placebo. Limited data were available for bleeding therefore no conclusions 35 
could be made.  36 
Conclusions: For non-hysterectomized women, transdermal O+P was the most effective treatment 37 
for VMS relief. 38 
Keywords: menopause, uterus, network meta-analysis, hormonal treatment. 39 
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 40 
 41 
Tweetable abstract: Which treatment best relieves menopause flushes? Results from the #NICE 42 
guideline network meta-analysis 43 
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 44 
Introduction  45 
Menopausal symptoms are extremely common. Vasomotor symptoms (VMS) comprising hot flushes 46 
and night sweats are the most common menopausal symptoms occurring in approximately 75% of 47 
postmenopausal women, with 25% of these being severely affected in the UK1. The duration and 48 
severity of menopausal symptoms experienced are not uniform – symptoms may develop in the 49 
years before the final menstrual period and may persist for a few years or for many years in 50 
postmenopause.  51 
Hot flushes often begin as the sudden sensation of heat centred on the upper chest and face. In 52 
some instances, this will become generalised, lasting for several minutes, and can be associated with 53 
profuse perspiration, palpitations or anxiety which may be very distressing and limit activities of 54 
daily living, particularly when they occur repeatedly during the day and at night. At night, hot flushes 55 
and night sweats will often cause insomnia that leads to fatigue. The mechanism of VMS appears to 56 
involve the central nervous system, possibly due to narrowing of the thermoregulatory-neutral zone 57 
in women with hot flushes, associated with instability of the skin blood vessels2.  58 
Different treatment options, pharmacological and non-pharmacological, have been used by women 59 
to relieve the VMS during menopause. Some of these treatments, such as hormone replacement 60 
therapy (HRT) target a “replacement” of oestrogen levels HRT comprises synthetic hormones 61 
including oestradiol, conjugated equine oestrogens, oestradiol valerate and several synthetic 62 
progestogens as well as tibolone which exhibits estrogenic, progestogenic and androgenic effects. 63 
Other treatments, such as herbal medicines and psychological therapies may work in different ways. 64 
As VMS may resolve naturally, some women simply do not wish to take hormones, while for others 65 
HRT is contraindicated, for example women who have (or are at high risk of) hormone-dependent 66 
cancer.  67 
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We aim to present the evidence obtained via a systematic review (SR), using network meta-analysis 68 
(NMA), of pharmacological and non-pharmacological treatments for the relief of VMS, relief of 69 
adverse events (such as vaginal bleeding)and discontinuation. This NMA formed part of the evidence 70 
underpinned the development of National Institute of Health and Care Excellence (NICE) Menopause 71 
Guideline (NG23) (https://www.nice.org.uk/guidance/ng23 )3.  The use of NMA is recommended in 72 
healthcare decision making when multiple treatments are considered for one indication and these 73 
treatments have not been directly compared in the same trials.  74 
Methods 75 
Systematic Reviews 76 
The protocol of the SR was agreed by the Guideline Development Group (GDG) (Appendix S1), was 77 
conducted as part of the development of NICE guideline on menopause (NG23) 78 
https://www.nice.org.uk/guidance/ng23 and is reported according to the PRISMA extension 79 
statement for systematic reviews incorporating NMAs of health care interventions4.. A cost-80 
effectiveness model using results from this NMA, in addition to other evidence, were used by the 81 
GDG to make recommendations in the guideline. In summary, the SRs included only randomised 82 
controlled trials (RCTs) that assessed pharmacological and/or non-pharmacological treatments for 83 
reducing the frequency of VMS, treatment discontinuation and vaginal bleeding for women aged 45 84 
years or older with a diagnosis of natural menopause (defined as amenorrhea for at least 12 85 
consecutive months).  86 
The population in the NMA protocol was stratified into three groups that formed three networks of 87 
connected treatments: women with a uterus, women without a uterus, women with a history or at 88 
risk of breast cancer. This paper presents the results of the first network (women with a uterus). For 89 
non-oestrogenic treatments we included studies of women without a uterus as their effect was 90 
found to be clinically similar. For studies investigating oestrogen plus progestogen we included 91 
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mixed studies of women with a uterus and without a uterus as long as more than two thirds (66.6%) 92 
of the study sample were women with a uterus (Appendix S1). 93 
The efficacy endpoint was the frequency of VMS at the end of treatment, whereas vaginal bleeding 94 
and treatment discontinuation were considered measures of adverse events. Although distress 95 
caused by VMS may have been an equal relevant outcome for women in menopause, the frequency 96 
of VMS was the most commonly reported outcome in studies, and the Guideline Committee 97 
highlighted that VMS were highly prevalent among women seeking treatment for menopausal 98 
symptoms. Vaginal bleeding and treatment discontinuation were prioritised due to their importance 99 
on continuity of healthcare, costs of further treatment, and long-term impact. . 100 
The time points of outcomes recorded were guided by clinical decision on the minimum duration of 101 
a trial for the intervention to be effective.  Non-hormonal treatments were considered by the GDG 102 
to take a minimum of four weeks to be effective, whilst hormonal treatments were considered to 103 
take longer (12 weeks). As shorter-term outcomes were the focus of this review, 26 weeks was 104 
considered to be the maximum follow-up time we would include, to avoid long-term changes in 105 
treatment efficacy that might cause heterogeneity within the network. 106 
All searches were conducted in MEDLINE  Embase and The Cochrane Library up to 13th January 2015 107 
restricted to English written articles according to the parameters stipulated within the NICE 108 
Guidelines Manual 2015 (https://www.nice.org.uk/article/PMG20/chapter/4-Developing-review-109 
questions-and-planning-the-evidence-review) (Appendix S2),.  Literature reviews, posters, letters, 110 
editorials, comment articles, unpublished studies and studies not in English were excluded. Full 111 
search strategies were published as part of the full NICE guideline 112 
(http://www.nice.org.uk/guidance/ng23/evidence/appendices-ag-559549262 ). 113 
Search strategies were quality assured by cross-checking reference lists of highly relevant papers and 114 
comparing with search strategies in other SRs. 115 
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Data extraction 116 
Data were double extracted in a structured form using a guide developed by the authors for Data 117 
Extraction for Complex Meta-anALysis (DECiMAL) independently by two reviewers55.  Discrepancies 118 
in data extraction were addressed by a senior reviewer who resolved any conflicts.  119 
The quality of the studies was evaluated using two domains (risk of bias, indirectness) of the 120 
‘Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox’ 121 
developed by the international GRADE working group (http://www.gradeworkinggroup.org/)6. 122 
Detailed results for risk of bias domains are shown in Table S2. 123 
Statistical models 124 
NMA was formulated to synthesise direct and indirect evidence of treatments’ effects to reduce the 125 
frequency of VMS, treatment discontinuation and vaginal bleeding using the software WinBUGS 126 
version 1.4.3. We used statistical models for both fixed and random effects that allowed inclusion of 127 
multi-arm trials and accounted for the correlation between arms in the trials with any number of 128 
trial arms7. A class effect model was selected for the NMA with the underlying assumption that the 129 
effectiveness of different treatments under the same class would be comparable. This decision was 130 
made to maximise the availability of data and borrow strength from different trials. Data were 131 
available on dosing for many treatments, but the sparseness of the networks meant that it was 132 
necessary to borrow strength on dosing within treatments by assuming different doses of the same 133 
treatment had the same class effects (fixed effects model (FE)). A model allowing for within-class 134 
variability was also assessed to check if it improved model fit and reduced heterogeneity (random 135 
effects model (RE)). Two RE models for this were explored: an exchangeable dose effects model, 136 
where the pooled relative effects of different treatment doses were assumed to be randomly 137 
distributed within each treatment with a common variance (requiring modelling using a second 138 
variance parameter); and a fixed dose effects model, where the pooled relative dose effects are 139 
assumed equal for all doses of a treatment. For treatments where dosing information was not 140 
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available, the relative effect at the dose level was assumed to be equal to the treatment effect in 141 
both models. 142 
WinBUGS code was adapted from the Dias et al 2011 and is available from the NICE appendices 143 
(https://www.nice.org.uk/guidance/ng23/evidence/appendices-ik-559549264 ). The following prior 144 
distributions were used: 145 
• Log mean ratios (MRs)  in the comparator arms for each study were normally distributed 146 
with mean of zero and variance of 1000 147 
• Pooled log MRs at the treatment or class level (depending on model used) were normally 148 
distributed with mean of zero and variance of 1000 149 
• Between-study standard deviation followed a uniform distribution between zero and two 150 
• Within-class standard deviation followed a uniform distribution between zero and two 151 
Placebo was selected as the baseline comparator for all networks as it was the treatment arm most 152 
commonly evaluated in RCTs.  As no dependency on time was identified in exploratory analyses, 153 
discontinuation of treatment and vaginal bleeding were treated as dichotomous outcomes and were 154 
modelled on the log-odds ratio scale (Figure S2). Exploratory analyses also showed that baseline 155 
frequency of VMS followed an overdispersed Poisson distribution thus it was not appropriate to use 156 
a standard Poisson distribution to model the frequency of VMS (Figure S3). The negative binomial 157 
distribution can be used to model an overdispersed Poisson distribution, by including a parameter 158 
that accounts for the overdispersion8,9,10. The mean of this negative binomial is interpreted as the 159 
rate of the over-dispersed Poisson and  can be approximated by a normal distribution. We therefore 160 
model the mean using a log link function and relative treatment effects are estimated as log-mean 161 
ratios. Our motivation was to model data as closely as possible to the mechanism by which they 162 
were generated (i.e. from an overdispersed Poisson distribution) and this approximation provided a 163 
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simple computational solution whilst retaining the interpretation of the pooled effect as mean rates 164 
of VMS 165 
On the log mean ratio scale, final and change from baseline frequencies of VMS could not be pooled, 166 
so the latter was transformed so that all effects could be modelled as final frequencies. A correlation 167 
coefficient of 0.55 was used to estimate final frequencies from change from baseline This was 168 
calculated from two included studies which reported baseline, final and change from baseline results 169 
in full11,12. 170 
All three models (FE, RE with fixed dose effects, RE with exchangeable dose effects) were compared 171 
based on residual deviance and deviance information criteria (DIC)7,13. Between-studies 172 
heterogeneity estimates from random effects models are presented as median and 95% credible 173 
intervals (95%CrI). 174 
Inconsistency in the networks was tested in closed loops of treatment comparisons by node-175 
splitting14. This technique allows the splitting of direct and indirect information contributing to each 176 
treatment effect. The difference between these contributions can be statistically tested, with a 177 
rejection of the null hypothesis indicating significant inconsistency in the network. 178 
The output of the NMA was expressed as the probability of each treatment being the best for an 179 
outcome (based on the proportion of Markov chain simulations in which a treatment ranked first) 180 
and the ranking of treatments (presented as median rank and its 95%CrI). The estimation of 181 
summary estimates (mean ratios [MRs] or odds ratios [ORs]) were also calculated for comparisons of 182 
the direct and indirect evidence using medians and 95%CrIs from the posterior distributions.   183 
Two types of sensitivity analyses were predefined in the NMA protocol. The first focused on 184 
changing the value of the correlation coefficient used to estimate final frequencies of VMS from 185 
change from baseline, from 0.55 in the original analysis to a typically assumed correlation between 186 
baseline and follow-up of 0.75. The second analysis tested if differences in treatment efficacy could 187 
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be explained by differences in dosing. Studies investigating the treatment of low dose oral oestradiol 188 
plus progestogen were removed from the analysis to determine if this dose was reducing the overall 189 
efficacy of oral oestradiol plus progestogen in the model. The final results were not found to be 190 
sensitive to either of these changes. 191 
A further post-hoc sensitivity analysis was considered to investigate the effect of including mixed 192 
population studies (women with and without a uterus) of oestrogen plus progestogen. However, as 193 
there was only a single study32 that included mixed populations for this treatment comparison, 194 
exclusion of the study removed oestrogen plus progestogen oral from the network and prevented 195 
estimation of the efficacy of this treatment. No other results were affected by the exclusion of this 196 
study. 197 
 198 
Results  199 
47 RCTs matched the protocol, presented information for at least one of the outcomes and were 200 
included in the NMA (Figure S1).  For the two first networks (frequency of VMS and discontinuation 201 
of treatment), DIC suggested that there was a small difference between any of the models 202 
(differences less than 5 points are not considered meaningful) (Tables S7). However, the residual 203 
deviance for the random effects model with fixed dose effects for both these networks was slightly 204 
closer to the number of unconstrained data points than either of the other models (for the fixed 205 
effects and random effects with exchangeable dose effects respectively). Therefore, the results of 206 
the random effects model with fixed dose effects are presented for these two networks. For the 207 
network of vaginal bleeding, the results of the fixed effects model are presented, as the estimate of 208 
heterogeneity for the random effects model was unstable, and strongly influenced by the prior 209 
distribution. 210 
 211 
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a. Reducing the frequency of VMS 212 
A total of 32 RCTs of 12 treatment classes (placebo, sham acupuncture, oestrogen plus progestogen 213 
non-oral, oestrogen plus progestogen oral, tibolone, raloxifene, SSRIs/SNRIs, isoflavones, Chinese 214 
herbal medicine, black cohosh, multibotanicals, acupuncture) with a sample size of 4165 women 215 
were included for the NMA for VMS (Figure 1, Table S1). Two included RCTs was at very high risk of 216 
bias and 13 were high risk (Table S2). The other 21 RCTs were low or moderate risk. The combination 217 
of oestrogen plus progestogen via patches was found to be better than placebo (MR 0.23 95%CrI 218 
(0.09, 0.57)) at relieving VMS for women in menopause and had the highest probability of being the 219 
best treatment (68.9%) (Figure 2A, Table 1). Although, the 95%CrI for combination of oral oestrogen 220 
plus progesterone compared to placebo was wide (MR 0.52 (0.25, 1.06)), the point estimate 221 
suggested that it may have good efficacy, similar to that of transdermal oestrogen plus progestogen. 222 
In addition, there was strong evidence to suggest that the combination of oestrogen plus 223 
progestogen via patches was more effective than raloxifene, SSRIs/SNRIs, isoflavones and Chinese 224 
herbal medicine in relieving VMS. Isoflavones and black cohosh were also found to be better than 225 
placebo. There was no strong evidence of any other effects among other interventions in the 226 
network (Table S3). 227 
High heterogeneity was found between studies, reducing the precision of estimates. This is likely to 228 
have arisen because of the clinical differences in patients included in the studies – the baseline 229 
frequency of hot flushes varied considerably between studies. Inconsistency was assessed in the 230 
closed loop between placebo, sham acupuncture and acupuncture, but no difference was found 231 
between results obtained through direct and indirect evidence (Table S3). 232 
a. Treatment discontinuation 233 
A total of 21 RCTs of 10 treatment classes (placebo, oestrogen plus progestogen oral, conjugated 234 
oestrogens plus bazedoxifene, tibolone, SSRIs/SNRIs, gabapentin, isoflavones, Chinese herbal 235 
medicine, multibotanicals, valerian root) with a sample size of 4829 women were included in the 236 
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network for discontinuation of treatment (Figure 1, Table S1). Because of high heterogeneity 237 
between the studies included in the NMA, uncertainty of the results was increased. Inconsistency 238 
could not be assessed in this network as there were no closed-treatment loops. Only 4 RCTs were at 239 
high risk of bias. The other 17 were low or moderate risk (Table S2). There was evidence that the 240 
combination of non-oral oestrogen plus progestogen had significantly lower odds of discontinuation 241 
than than placebo (OR 0.61 95%CrI (0.37, 0.99). In addition, there was evidence that conjugated 242 
oestrogens plus bazedoxifene (OR 0.31 95%CrI (0.1, 1.00)) was more effective than placebo in this 243 
outcome, although there was considerable uncertainty in this result. There was strong evidence that 244 
SSRIs/SSNIs were worse than placebo (OR 1.66 95%CrI (1.07, 2.61)) on discontinuation of treatment. 245 
There was evidence that Tibolone and SSRIs/SNRIs were worse than non-oral oestrogen plus 246 
progestogen and conjugated oestrogens plus bazedoxifene for this outcome (Figure 2B, Table 2, 247 
Table S4). 248 
In this analysis, conjugated oestrogens plus bazedoxifene and valerian root were found to have the 249 
highest probability (37.34% and 37% respectively) of being the best treatments in relation to 250 
discontinuation of treatment among interventions with duration up to 26 weeks, although note that 251 
these probabilities are small and below 50%  252 
a. Vaginal bleeding 253 
The network of vaginal bleeding included five RCTs of 5 treatment classes (placebo, oestrogen plus 254 
progestogen oral, tibolone, SSRIs/SNRIs, gabapentin) (Figure 1, Table S1) with a sample size of 1367 255 
women. Neither heterogeneity nor inconsistency could be assessed in the network due to its 256 
sparseness. A fixed effects model was used and there were no closed-treatment loops. One study 257 
was at high risk of bias, one was low risk, and the other three were moderate risk (Table S2). The 258 
sparseness of data within the network meant that there was a high degree of uncertainty in 259 
estimates, and no conclusions could be drawn regarding effects of treatments on vaginal bleeding 260 
(adverse event) (Figure 2C, Table S5, Table S6). 261 
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 262 
Discussion  263 
This paper summarizes the evidence included in three SRs and analysed in NMAs for the outcomes 264 
of relief of frequency of VMS, treatment discontinuation and vaginal bleeding among 265 
pharmacological and non-pharmacological treatments for women with a uterus who have 266 
undergone a natural menopause. To our knowledge, this is the first publication using this type of 267 
complex analysis in the research field of menopause. 268 
Main findings 269 
NMA results showed that for women with a uterus, the oestrogen plus progestogen transdermal 270 
patch was the most effective treatment to relieve the frequency of VMS, with a lower odds of 271 
discontinuation compared with all the other available treatments (hormonal, non-hormonal and 272 
non-pharmacological). There was evidence that oestrogen plus progestogen taken orally may be 273 
more effective to relieve VMS than placebo, but this did not rank as highly as transdermal oestrogen 274 
plus progestogen in the hierarchy of the best treatment options for this outcome. However, in the 275 
clinical setting both may be considered as options, depending on the individual’s response to 276 
treatment. Although isoflavones and black cohosh, were also shown to be more effective than 277 
placebo in relief of VMS for women with a uterus, there was no evidence that their efficacy differed 278 
from combined oestrogen plus progestogen. However, these results should be interpreted with 279 
caution as there was a variety of herbal preparations used in different studies. SSRIs/SNRIs were not 280 
found to be effective in relieving VMS but were found to have higher odds of discontinuation 281 
compared to the other treatments, as would be expected due to the serious side effects profile of 282 
these treatments. However, the NMA demonstrated that women treated with non-oral oestradiol 283 
plus progestogen or with conjugated oestrogens plus bazedoxifene were less likely to discontinue 284 
treatment than if they were treated with placebo or tibolone.  285 
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No conclusive points could be made for the outcome of vaginal bleeding for women with a uterus 286 
given the limited data for this outcome and the lack of inclusion of several interventions in the 287 
network.  288 
During the NICE guideline development, results of clinical efficacy from the NMA were incorporated 289 
into a probabilistic cost-effectiveness analysis that informed the decision-making of the Guideline 290 
Committee. The Committeeconcluded that women with a uterus should be offered the treatment of 291 
oestrogen and progestogen (HRT) for the relief of VMS, following an individualized approach and 292 
after discussing with them the short-term (up to 5 years) and longer-term benefits and risks. Health 293 
professionals should not routinely offer selective serotonin reuptake inhibitors (SSRIs), serotonin and 294 
norepinephrine reuptake inhibitors (SNRIs) or clonidine as first-line treatment for VMS alone and 295 
should explain to women that although there is some evidence that isoflavones or black cohosh may 296 
relieve VMS there are health concerns in relation to safety of multiple preparations and interactions 297 
with other medicines (https://www.nice.org.uk/guidance/ng23/ ) 298 
Strengths and Limitations 299 
This is the first NMA designed to include simultaneous comparison of randomized evidence aiming 300 
to reduce the frequency of VMS for women in menopause. Advanced statistical techniques were 301 
employed to make best use of available evidence. A novel NMA model which accounts for the nature 302 
of the VMS data, distributed as overdispersed Poisson, and incorporates class effects and 303 
transformation of change from baseline scores of outcomes, was developed to make use of as much 304 
relevant and available data as possible. We were therefore simultaneously able to compare several 305 
interventions of interest to women and policy makers that had not been compared previously in 306 
head-to-head trials. 307 
Overall there were relatively few studies included in the networks compared to the number of 308 
treatment comparisons. This may have led to the within-class standard deviation parameter not 309 
being fully informed, which could explain the better fit of the fixed dose effect RE model compared 310 
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to the exchangeable dose effect RE model. A dose-response relationship might have been expected 311 
in the data, but as the protocol specified that treatments had to be administered within selective 312 
doses specified in the British National Formulary, the range of doses was often very small. 313 
Furthermore, body weights and absorption can vary substantially between patients, and this is likely 314 
to lead to as much (if not more) variation in bioavailability of treatment than the administered dose.  315 
Several decisions were made at the protocol stage that impacted the selection of data included in 316 
the networks and therefore the representativeness of all available evidence in this area. For 317 
example, we included only English-published studies , which may have limited our evidence on some 318 
treatments (e.g. Chinese herbal medicines), and publication bias was not easily assessed. 319 
Furthermore, it was decided to examine the role of different treatments used to reduce the 320 
frequency rather than the severity of VMS, which resulted in some treatments such as cognitive 321 
behaviour therapy being excluded from the NMA. The selection of outcomes for inclusion in the 322 
NMA was based on both their clinical importance and relevance to women in menopause. 323 
Frequency of VMS, discontinuation and vaginal bleeding were prioritised for inclusion due to their 324 
high prevalence and availability of evidence. 325 
Assumptions were also made for the minimum duration of trials for inclusion in the NMA and the 326 
minimum acceptable criteria for mixed population studies. These assumptions are commonly made 327 
when a complex meta-analysis is designed and aim to increase the homogeneity and validity of 328 
included data. However, this resulted in a number of studies being excluded from further analysis. 329 
Some studies were also excluded because the data reported did not give an indication of variability 330 
(no information on standard deviation or standard error of results). For the small minority of studies 331 
that were excluded because they did not connect to the network, their results and whether they 332 
would influence decision-making were further discussed with the GDG. This information was used as 333 
supplementary evidence to facilitate the Group’s discussion which recognised the importance of 334 
these treatments in the management of some women with menopause, especially if they do not 335 
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wish to be treated with pharmacological treatments (such as HRT) and these options were 336 
highlighted in terms of provision of general advice and information.  337 
Interpretation 338 
This is the first NMA designed to include simultaneous comparison of randomized evidence from 339 
pharmacological and non-pharmacological treatments aiming to reduce the frequency of VMS for 340 
women in menopause. After taking into account the assumptions used for this NMA and the 341 
limitations of this approach, these results provided a comprehensive framework for decision making 342 
by combing direct and indirect evidence on treatments for the relief of VMS in menopause. Our 343 
reviewed literature did not identify any other similar type of analysis that could be used for our 344 
results comparison.   345 
 346 
Conclusions 347 
There is evidence that transdermal oestradiol plus progestogen greatly reduces the frequency of hot 348 
flushes in women with a uterus. Although there is some evidence of efficacy of oral oestrogen plus 349 
progestogen treatment, the health economic analysis and the GDG’s expert opinion supported the 350 
use of both types of oestradiol plus progestogen’s administration in clinical practice. 351 
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Table 1: Log mean ratios (with their 95% CI) of all interventions in the network and the probability 
of being the best treatment for reducing the frequency of VMS 
Median 
log mean 
ratios 95%CrI 
Probability of being 
the best treatment 
Median (95% CrI) 
treatment rank 
Placebo Reference treatment 0.00% 10 (7-12) 
Sham acupuncture -0.30  (-1.32, 0.64) 1.44% 7 (2-12) 
Oestrogen + progestogen 
non-oral 
-1.46  (-2.37, -0.56) 69.82% 1 (1-5) 
Oestrogen + progestogen oral -0.67  (-1.4, 0.06) 3.73% 4 (1-10) 
Tibolone -0.60  (-1.45, 0.25) 4.02% 5 (1-11) 
Raloxifine 0.50  (-0.49, 1.51) 0.04% 12 (6-12) 
SSRIs/SNRIs -0.17  (-0.61, 0.26) 0.01% 8 (4-11 ) 
Isoflavones -0.48  (-0.82, -0.13) 0.10% 6 (3-9 ) 
Chinese herbal medicine  -0.05  (-0.78, 0.63) 0.09% 9 (4-12 ) 
Black cohosh -0.92  (-1.8, -0.11) 14.23% 3 (1-9 ) 
Multibotanicals  -0.34  (-1.43, 0.73) 2.88% 7 (1-12 ) 
Acupuncture -0.54  (-1.49, 0.31) 3.64% 5 (1-11 ) 
Between-study heterogeneity:  Standard deviation on the log MRs scale (SD) (95% CrI) 0.50 (0.37, 0.70) 
 
Table 2: Log odd ratios (with their 95% CrI) of all interventions in the network and the probability 
of being the best treatment for discontinuation of treatment 
Median log 
odds ratios 95%CrI 
Probability of 
being the best 
treatment 
Median (95% 
CrI) treatment 
rank 
Placebo Reference treatment 0.00% 6 (4-8) 
Oestrogen + progestogen oral -0.50  (-0.99, -0.01) 2.83% 3 (1-6 ) 
Conjugated oestrogens plus 
bazedoxifene  
-1.16  (-2.28, 0.002) 37.34% 2 (1-6 ) 
Tibolone 1.73  (-0.06, 5.15) 0.03% 10 (6-10 ) 
SSRIs/SNRIs 0.50  (0.06, 0.96) 0.00% 8 (6-10 ) 
Gabapentin -0.13  (-0.46, 0.21) 0.08% 5 (3-8 ) 
Isoflavones -0.05  (-0.67, 0.57) 0.29% 6 (2-9 ) 
Chinese herbal medicine  0.46  (-0.86, 1.9) 0.66% 8 (2-10 ) 
Multibotanicals  -0.70  (-2.63, 1.51) 21.77% 3 (1-10 ) 
Valerian root -0.91  (-4.41, 1.69) 37.00% 2 (1-10 ) 
Between-study heterogeneity:  Standard deviation on the log MRs scale (SD) (95% CrI) 0.25 (0.01, 0.70) 
 
